Eli's Gone
8年前
CC slides:
https://www.abcannglobal.com/assets/Abcann%20-%20Special%20Information%20Circular.pdf
A conference call to discuss the Transaction will take place on Tuesday July 31, 2018 at 9:00
a.m. ET (details below).
July 31, 2018 Conference Call Information:
ABcann will host a conference call, including a slide presentation that will be posted on the Company’s website
(www.abcannglobal.com), to discuss the Transaction on Tuesday, July 31, 2018 at 9:00 a.m. ET. Participants may join the
conference call by dialing 1-855-353-9183 from Canada or the USA using the participant passcode 45136#.
Icymanx
8年前
StockCharts.com
Search StockCharts
Enter Symbol or Company Name
Free Tools
Blog Articles
StockCharts TV
ChartSchool
Members Dashboard
Help
Log In
Sign Up
Triple Bottom (Reversal)
Search StockCharts
Want ad-free charting? Join StockCharts! 1-Month Trial
StockCharts.com » ChartSchool » Chart Analysis » Chart Patterns » Triple Bottom (Reversal)
The Triple Bottom Reversal is a bullish reversal pattern typically found on bar charts, line charts and candlestick charts. There are three equal lows followed by a break above resistance. As major reversal patterns, these patterns usually form over a 3- to 6-month period. Note that a Triple Bottom Reversal on a bar or line chart is completely different from Triple Bottom Breakdown on a P&F chart. Namely, Triple Bottom Breakouts on P&F charts are bearish patterns that mark a downside support break. We will first examine the individual parts of the pattern and then look at an example.
Anadarko Petroleum Corp. (APC) Triple Bottom Reversal example chart from StockCharts.com
Prior Trend: With any reversal pattern, there should be an existing trend to reverse. In the case of the Triple Bottom Reversal, a clear downtrend should precede the formation.
Three Lows: All three lows should be reasonably equal, well-spaced and mark significant turning points. The lows do not have to be exactly equal, but should be reasonably equivalent.
Volume: As the Triple Bottom Reversal develops, overall volume levels usually decline. Volume sometimes increases near the lows. After the third low, an expansion of volume on the advance and at the resistance breakout greatly reinforces the soundness of the pattern.
Resistance Break: As with many other reversal patterns, the Triple Bottom Reversal is not complete until a resistance breakout. The highest point of the formation, which would be the highest of the intermittent highs, marks resistance.
Resistance Turns Support: Broken resistance becomes potential support, and there is sometimes a test of this newfound support level with the first correction.
Price Target: The distance from the resistance breakout to lows can be measured and added to the resistance break for a price target. The longer the pattern develops, the more significant is the ultimate breakout. Triple Bottom Reversals that are 6 or more months in duration represent major bottoms and a price target is less likely to be effective.
As the Triple Bottom Reversal develops, it can start to resemble a number of patterns. Before the third low forms, the pattern may look like a Double Bottom Reversal. Three equal lows can also be found in a descending triangle or rectangle. Of these patterns mentioned, only the descending triangle has bearish overtones; the others are neutral until a breakout occurs. Similarly, the Triple Bottom Reversal should also be treated as a neutral pattern until a breakout occurs. The ability to hold support is bullish, but demand has not won the battle until resistance is broken. Volume on the last advance can sometimes yield a clue. If there is a sharp increase in volume and momentum, then the chances of a breakout increase.
Andrew Corp. (ANDW) Triple Bottom Reversal example chart from StockCharts.com
After a failed double bottom breakout, ANDW formed a large Triple Bottom Reversal. While the new reaction high (black arrow) and potential double bottom breakout seemed bullish, the stock subsequently fell back to support.
Technically, the downtrend ended when the stock formed a higher low in Mar-99 and surpassed its Jan-99 high by closing above 20 in Jul-99 (black arrow). Even though the downtrend ended, it would have been difficult to label the trend bullish after the third test of support around 11.
Over a 13-month timeframe, three relatively equal lows formed in Oct-98, Mar-99, and Nov-99. When the Jul-00 high surpassed the Jan-99 high, the possibility of a rectangle pattern was ruled out.
Resistance at 22 1/2 was broken in Jan-00. The stock closed above this key level for 5 consecutive weeks to confirm the breakout.
Even though volume expanded near the second and third lows, the 10-day EMA of volume declined between the lows. The advance off of the third low saw a dramatic expansion of volume that lasted many weeks. The Accumulation/Distribution Line formed a positive divergence in 1999 and broke to new highs with the stock in Jan-00.
After the resistance break, the stock fell below 22 1/2 twice over the next 2 months. Based on the Feb-00 and Apr-00 lows, a new support level was established at 20 and. Because upside movement was limited after the breakout (a high of 25 1/2), a pullback below 22 1/2 might have been expected. Based on Oct-99 resistance, critical support could have been marked at 18 1/2.
ANDW built a base over a 13-month period. Even though the height of the pattern is relatively impressive, it pales in comparison to the length of the base. The length of this pattern and subsequent breakout suggest a long-term change of sentiment.
Sign up for our FREE twice-monthly ChartWatchers Newsletter!
Your Email Address
Charting Tools
SharpCharts
Point & Figure
PerfCharts
CandleGlance Groups
Seasonality
GalleryView
RRG Charts
Dynamic Yield Curve
ChartSchool
Overview
Glossary
Chart Analysis
Indicators & Overlays
Market Analysis
Charting Resources
Scanning Resources
Trading Strategies & Models
Blogs
John Murphy
Art's Charts
ChartWatchers
DecisionPoint
Don't Ignore This Chart
The Canadian Technician
The Traders Journal
Trading Places
More Resources
About Us
FAQs
Site Map
Symbol Catalog
Support Center
Instructional Videos
Pricing & Features
The StockCharts Store
© StockCharts.com, Inc. All Rights Reserved.
Terms of Service Privacy Statement
Market data provided by: Interactive Data Corporation. Commodity and historical index data provided by: Pinnacle Data Corporation. Unless otherwise indicated, all data is delayed by 15 minutes. The information provided by StockCharts.com, Inc. is not investment advice. Trading and investing in financial markets involves risk. You are responsible for your own investment decisions.
Icymanx
8年前
Your News Wire
Trump Set To Legalize Medical Marijuana In All 50 States
Baxter Dmitry
3 days ago
President Trump is set to sign legislation which will make medical marijuana federally legal for terminally ill patients.
President Trump is set to sign legislation which will make medical marijuana federally legal for terminally ill patients. The bill, known as the “Right to Try Act,” will prohibit the FDA from banning natural cures, and allow patients to try medications that have not been approved by the FDA, but are currently under clinical trial.
Right to Try was passed unanimously by the Senate last summer and by the House of Representatives on Tuesday in a vote of 250 to 169, after Trump personally lobbied for its passage. While the bill’s provisions are targeted at a wide range of medications, they also apply to medical marijuana thanks to a clinical trial being conducted by the Multidisciplinary Association of Psychedelic Sciences (MAPS).
Herb reports: The MAPS trial, currently in the second phase of the FDA approval process, is testing the effectiveness of smoked cannabis in veterans with PTSD and meets all of the criteria set out by the Right to Try.
The majority of states already have their own form of Right to Try legislation, with one notable exception being New York. In Utah, a recently passed law specifically addresses the right of terminally ill patients to try cannabis. However, because cannabis remains federally prohibited, even if a terminally ill patient has the “Right to Try” cannabis on the state level, they’re still in violation of federal law.
The Right to Try bill, recently passed by Congress, would change that. In addition to cannabis, MDMA and psilocybin could also potentially be used by ‘eligible patients’ since FDA trials of both substances meet the requirements set out in the federal bill.
What’s not clear is what illnesses qualify as life-threatening. Post-traumatic stress disorder, for example, could be argued to be life-threatening given the high rates of suicide among those who are diagnosed, but it’s up for debate. It’s likely that those details will be hammered out on a state by state basis in jurisdictions that have already passed their own version of Right to Try. The full title of the bill suggests as much stating, “in accordance with State law…”
However, in states that lack their own local provisions, the new bill appears to leave plenty of room for interpretation and a potential conflict with local drug laws.
Under the broad wording of the federal bill, no specific illnesses are mentioned. Instead, an ‘eligible patient’ is defined as, “Diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted; and Diseases or conditions with potentially fatal outcomes, where the endpoint of clinical trial analysis is survival.”
Patients must also have exhausted all existing treatment options and must be unable to participate in the ongoing trials investigating the drug they want access to. Additionally, they must provide written consent from a qualified physician who does not stand to gain from the trial.
The bill passed on Tuesday after receiving some opposition from Democrats on Capitol Hill who believe that the law will undermine the FDA’s processes.
It’s likely that President Trump will sign the bill in the coming days since he has personally lobbied Congress for its passage. In January, Trump even mentioned the bill in his State of the Union Address saying, “People who are terminally ill should not have to go from country to country to seek a cure. I want to give them a chance right here at home. It is time for the Congress to give these wonderful, incredible Americans the right to try.”
Early Wednesday morning, Trump reiterated his support for the bill tweeting his intention to sign it into law.
Loading ...
Categories: News, US
Leave a Comment
Your News Wire
Powered by WordPress
Back to top
Icymanx
8年前
ScienceDaily
Your source for the latest research news
advertisement
Science Newsfrom research organizations
Cannabinoids remove plaque-forming Alzheimer's proteins from brain cells
Date:
June 29, 2016
Source:
Salk Institute
Summary:
Scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer's disease.
Share:
FULL STORY
Preliminary lab studies by Salk Professor David Schubert suggest that the molecule THC reduces beta amyloid proteins in human neurons.
Credit: Salk Institute
Salk Institute scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer's disease.
advertisement
While these exploratory studies were conducted in neurons grown in the laboratory, they may offer insight into the role of inflammation in Alzheimer's disease and could provide clues to developing novel therapeutics for the disorder.
"Although other studies have offered evidence that cannabinoids might be neuroprotective against the symptoms of Alzheimer's, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells," says Salk Professor David Schubert, the senior author of the paper.
Alzheimer's disease is a progressive brain disorder that leads to memory loss and can seriously impair a person's ability to carry out daily tasks. It affects more than five million Americans according to the National Institutes of Health, and is a leading cause of death. It is also the most common cause of dementia and its incidence is expected to triple during the next 50 years.
It has long been known that amyloid beta accumulates within the nerve cells of the aging brain well before the appearance of Alzheimer's disease symptoms and plaques. Amyloid beta is a major component of the plaque deposits that are a hallmark of the disease. But the precise role of amyloid beta and the plaques it forms in the disease process remains unclear.
In a manuscript published in June 2016's Aging and Mechanisms of Disease, Salk team studied nerve cells altered to produce high levels of amyloid beta to mimic aspects of Alzheimer's disease.
The researchers found that high levels of amyloid beta were associated with cellular inflammation and higher rates of neuron death. They demonstrated that exposing the cells to THC reduced amyloid beta protein levels and eliminated the inflammatory response from the nerve cells caused by the protein, thereby allowing the nerve cells to survive.
"Inflammation within the brain is a major component of the damage associated with Alzheimer's disease, but it has always been assumed that this response was coming from immune-like cells in the brain, not the nerve cells themselves," says Antonio Currais, a postdoctoral researcher in Schubert's laboratory and first author of the paper. "When we were able to identify the molecular basis of the inflammatory response to amyloid beta, it became clear that THC-like compounds that the nerve cells make themselves may be involved in protecting the cells from dying."
Brain cells have switches known as receptors that can be activated by endocannabinoids, a class of lipid molecules made by the body that are used for intercellular signaling in the brain. The psychoactive effects of marijuana are caused by THC, a molecule similar in activity to endocannabinoids that can activate the same receptors. Physical activity results in the production of endocannabinoids and some studies have shown that exercise may slow the progression of Alzheimer's disease.
Schubert emphasized that his team's findings were conducted in exploratory laboratory models, and that the use of THC-like compounds as a therapy would need to be tested in clinical trials.
In separate but related research, his lab found an Alzheimer's drug candidate called J147 that also removes amyloid beta from nerve cells and reduces the inflammatory response in both nerve cells and the brain. It was the study of J147 that led the scientists to discover that endocannabinoids are involved in the removal of amyloid beta and the reduction of inflammation.
Other authors on the paper include Oswald Quehenberger and Aaron Armando at the University of California, San Diego; and Pamela Maher and Daniel Daughtery at the Salk Institute.
The study was supported by the National Institutes of Health, The Burns Foundation and The Bundy Foundation.
advertisement
Story Source:
Materials provided by Salk Institute. Note: Content may be edited for style and length.
Journal Reference:
Antonio Currais, Oswald Quehenberger, Aaron M Armando, Daniel Daugherty, Pam Maher, David Schubert. Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. npj Aging and Mechanisms of Disease, 2016; 2: 16012 DOI: 10.1038/npjamd.2016.12
Cite This Page:
MLA
APA
Chicago
Salk Institute. "Cannabinoids remove plaque-forming Alzheimer's proteins from brain cells." ScienceDaily. ScienceDaily, 29 June 2016. <www.sciencedaily.com/releases/2016/06/160629095609.htm>.
advertisement
RELATED STORIES
New Player in Alzheimer's Disease Pathogenesis Identified
Nov. 14, 2017 — Scientists have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study shows that membralin regulates the cell's machinery for ... read more
Human Amyloid-Beta Acts as Natural Antibiotic in the Brain: Alzheimer's-Associated Amyloid Plaques May Trap Microbes
May 25, 2016 — A new study provides additional evidence that amyloid-beta protein -- which is deposited in the form of beta-amyloid plaques in the brains of patients with Alzheimer's disease -- is a normal ... read more
Genetic Variations That Boost PKC Enzyme Contribute to Alzheimer's Disease
May 10, 2016 — In Alzheimer's disease, plaques of amyloid beta protein accumulate in the brain, damaging connections between neurons. Now, researchers have found that the enzyme Protein Kinase C (PKC) alpha is ... read more
Marijuana Compound May Offer Treatment for Alzheimer's Disease, Study Suggests
Aug. 27, 2014 — Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer's disease, a recent study from neuroscientists ... read more
FROM AROUND THE WEB
Below are relevant articles that may interest you. ScienceDaily shares links and proceeds with scholarly publications in the TrendMD network.
Toggle navigationMenu SD
Free Subscriptions
Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:
Email Newsletters
RSS Feeds
Follow Us
Keep up to date with the latest news from ScienceDaily via social networks:
Facebook
Twitter
Google+
LinkedIn
Have Feedback?
Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Leave Feedback
Contact Us
About This Site | Editorial Staff | Awards & Reviews | Contribute | Advertise | Privacy Policy | Terms of Use
Copyright 2018 ScienceDaily or by other parties, where indicated. All rights controlled by their respective owners.
Content on this website is for information only. It is not intended to provide medical or other professional advice.
Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners.
Financial support for ScienceDaily comes from advertisements and referral programs, where indicated.
Icymanx
8年前
ABcann Launches Beacon Medical
Print
Alert
Abcann Global Corporation (TSXV:ABCN)
Intraday Stock Chart
Today : Wednesday 23 May 2018
Click Here for more Abcann Global Corporation Charts.
ABcann Global Corporation (TSX-V:ABCN) (“ABcann” or the “Company”) is pleased to announce the launch of Beacon Medical, its new medical cannabis brand. The goal of Beacon Medical is to help patients and their healthcare providers navigate the complex medical cannabis market to find the best treatment option.
“Our vision is to leverage our unique experience in the global pharmaceutical industry to create one of the most respected medical cannabis companies. The launch of Beacon is an important step towards that vision,” stated Barry Fishman, Chief Executive Officer.
The adoption of the Beacon Medical brand is a direct result of an exclusive study of 1,500 Canadians that ABcann conducted in early 2018. The Company is committed to developing its brands based on deep consumer insights. ABcann’s study identified that 73% of adult Canadians who are not currently using cannabis, but have a treatable condition, say they lack the appropriate knowledge of how to use medical cannabis, and 67% say they are unfamiliar with how to obtain medical cannabis. With so many Canadians not clear about how to obtain and use medical cannabis, ABcann believes the market is ready for a brand that makes the process easier to navigate.
Beacon Medical will differentiate itself by focusing on the patient experience: simple registration and product classification, efficient purchasing, pharmaceutical-grade products, and compassionate customer service.
“A beacon is a symbol of hope and relief for those seeking guidance, and that’s why Beacon is a perfect metaphor and the ideal name for our new medical cannabis brand. We want to develop simple ways to help people navigate the complex world of cannabis,” stated Sung Kang, Chief Marketing Officer.
Beacon Medical invites investors, media and consumers to get a first glimpse of the new Beacon brand at the Lift Expo taking place in Toronto from May 25th to 27th, 2018. The full Beacon Medical website and product line, which will include the introduction of cannabis oils, will be available to ACMPR patients by early summer 2018.
About ABcann
ABcann is recognized for high-quality, trusted products and services. It holds production and sales licenses from Health Canada, and its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. ABcann is expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this news release may be considered forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of ABcann and its management regarding the future. Forward-looking statements in this news release include statements relating to: the expected legalization of the adult-use cannabis market; the expected launch time of the Beacon Medical product line and website; the expected impact of the Beacon Medical brand on the market; the Beacon Medical product line including cannabis oils; and ABcann’s goal of becoming one of the best and most respected medical cannabis business in Canada and internationally. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including the possibility that ABcann may not derive the expected benefits from the adoption of the Beacon Medical brand; that the market will not adopt the Beacon Medical brand; that the differentiating factors between the Beacon Medical product line and those of ABcann’s competitors will not materialize; that the adult-use market will not open as expected; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors, and the more extensive risk factors included in the Company’s annual information form dated April 30, 2018, which is available on SEDAR, carefully in evaluating the forward-looking statements contained in this news release, and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward-looking statements, whether because of new information, future events or results or otherwise, except as required by applicable securities laws.
For more information about ABcann, please contact:
Barry Fishman at barry.fishman@abcannglobal.com or
Michael Bumby at michael.bumby@abcannglobal.com
Icymanx
8年前
ABcann Launches Beacon Medical
Print
Alert
Abcann Global Corporation (TSXV:ABCN)
Intraday Stock Chart
Today : Wednesday 23 May 2018
Click Here for more Abcann Global Corporation Charts.
ABcann Global Corporation (TSX-V:ABCN) (“ABcann” or the “Company”) is pleased to announce the launch of Beacon Medical, its new medical cannabis brand. The goal of Beacon Medical is to help patients and their healthcare providers navigate the complex medical cannabis market to find the best treatment option.
“Our vision is to leverage our unique experience in the global pharmaceutical industry to create one of the most respected medical cannabis companies. The launch of Beacon is an important step towards that vision,” stated Barry Fishman, Chief Executive Officer.
The adoption of the Beacon Medical brand is a direct result of an exclusive study of 1,500 Canadians that ABcann conducted in early 2018. The Company is committed to developing its brands based on deep consumer insights. ABcann’s study identified that 73% of adult Canadians who are not currently using cannabis, but have a treatable condition, say they lack the appropriate knowledge of how to use medical cannabis, and 67% say they are unfamiliar with how to obtain medical cannabis. With so many Canadians not clear about how to obtain and use medical cannabis, ABcann believes the market is ready for a brand that makes the process easier to navigate.
Beacon Medical will differentiate itself by focusing on the patient experience: simple registration and product classification, efficient purchasing, pharmaceutical-grade products, and compassionate customer service.
“A beacon is a symbol of hope and relief for those seeking guidance, and that’s why Beacon is a perfect metaphor and the ideal name for our new medical cannabis brand. We want to develop simple ways to help people navigate the complex world of cannabis,” stated Sung Kang, Chief Marketing Officer.
Beacon Medical invites investors, media and consumers to get a first glimpse of the new Beacon brand at the Lift Expo taking place in Toronto from May 25th to 27th, 2018. The full Beacon Medical website and product line, which will include the introduction of cannabis oils, will be available to ACMPR patients by early summer 2018.
About ABcann
ABcann is recognized for high-quality, trusted products and services. It holds production and sales licenses from Health Canada, and its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. ABcann is expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this news release may be considered forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of ABcann and its management regarding the future. Forward-looking statements in this news release include statements relating to: the expected legalization of the adult-use cannabis market; the expected launch time of the Beacon Medical product line and website; the expected impact of the Beacon Medical brand on the market; the Beacon Medical product line including cannabis oils; and ABcann’s goal of becoming one of the best and most respected medical cannabis business in Canada and internationally. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including the possibility that ABcann may not derive the expected benefits from the adoption of the Beacon Medical brand; that the market will not adopt the Beacon Medical brand; that the differentiating factors between the Beacon Medical product line and those of ABcann’s competitors will not materialize; that the adult-use market will not open as expected; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors, and the more extensive risk factors included in the Company’s annual information form dated April 30, 2018, which is available on SEDAR, carefully in evaluating the forward-looking statements contained in this news release, and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward-looking statements, whether because of new information, future events or results or otherwise, except as required by applicable securities laws.
For more information about ABcann, please contact:
Barry Fishman at barry.fishman@abcannglobal.com or
Michael Bumby at michael.bumby@abcannglobal.com
GM26
8年前
ABcann Global Stands Out With Its Cannabis Cultivation Technologies
Sean Mason, SmallCapPower.com | Apr 22, 2018 01:42AM ET
h3 ABcann Global Corp (V:ABCN) estimates its revenues to grow multifold through 2021, reaching $500 million from less than $1.0 million run rate/h3
ABcann Global Corporation is a junior cannabis player holding a niche in cultivation technologies that deliver higher yields and consistent quality. ABcann is planning aggressive expansion of its flagship facility in Napanee, Ontario, with production targets of over 30,000 kgs annually by 2019.
https://www.investing.com/analysis/abcann-global-stands-out-with-its-cannabis-cultivation-technologies-200307587
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ihubstockmover
4年前
Golden Cross
4年前
メールアドレスで登録
